Small Molecule and Protein Docking Introduction
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Raman Imaging of Small Biomolecules
BB48CH15_Min ARjats.cls April 16, 2019 13:8 Annual Review of Biophysics Raman Imaging of Small Biomolecules Yihui Shen, Fanghao Hu, and Wei Min Department of Chemistry, Columbia University, New York, NY 10027, USA; email: [email protected] Annu. Rev. Biophys. 2019. 48:347–69 Keywords First published as a Review in Advance on Raman microscopy, small molecule imaging, vibrational tags, lipid March 20, 2019 metabolism, drug imaging The Annual Review of Biophysics is online at biophys.annualreviews.org Abstract Access provided by Columbia University on 06/21/19. For personal use only. https://doi.org/10.1146/annurev-biophys-052118- Imaging techniques greatly facilitate the comprehensive knowledge of Annu. Rev. Biophys. 2019.48:347-369. Downloaded from www.annualreviews.org 115500 biological systems. Although imaging methodology for biomacromolecules Copyright © 2019 by Annual Reviews. such as protein and nucleic acids has been long established, micro- All rights reserved scopic techniques and contrast mechanisms are relatively limited for small biomolecules, which are equally important participants in biological pro- cesses. Recent developments in Raman imaging, including both microscopy and tailored vibrational tags, have created exciting opportunities for non- invasive imaging of small biomolecules in living cells, tissues, and organ- isms. Here, we summarize the principle and workflow of small-biomolecule imaging by Raman microscopy. Then, we review recent efforts in imaging, for example, lipids, metabolites, and drugs. The unique advantage of Raman imaging has been manifested in a variety of applications that have provided novel biological insights. 347 BB48CH15_Min ARjats.cls April 16, 2019 13:8 Contents THENEEDFORIMAGINGSMALLBIOMOLECULES........................ 348 IMAGINGSMALLMOLECULESBYVIBRATIONALCONTRAST............. 349 LINEAR AND NONLINEAR RAMAN SCATTERING SPECTROSCOPY ANDMICROSCOPY......................................................... -
Small Molecules, Big Impact
FOR RESEARCH USE ONLY. NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES. STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485 MEDICAL DEVICE STANDARDS. TGFβ: The TGFβ superfamily members are major regulators of self-renewal and differentiation to mesendodermal lineages. p38 / p53: p38 MAPK is activated in response to cellular stresses, and influences apoptosis and cellular differentiation. p53 is activated in Pathway Activators: IDE1, IDE2; Pathway Inhibitors: SB431542, LY364947, RepSox, Dorsomorphin, LDN193189 response to cellular stresses and regulates growth arrest, apoptosis and/or DNA repair. Inhibition of p53 is used to facilitate reprogramming. Pathway Inhibitors: BIRB-796, SB202190, SB203580, Cyclic Pifithrin-α, Pifithrin-μ Hedgehog: The Hedgehog pathway is important in the differentiation of mesenchymal subtypes (e.g. osteocytes) and in neural subtypes (e.g. dopaminergic neurons). FGF: FGF signaling via MEK/ERK is critical for self-renewal and proliferation of human PSCs. However, other receptor tyrosine kinases can Pathway Activator: Purmorphamine; Pathway Inhibitors: Cyclopamine, HPI-1 also act through the MEK/ERK and PI3K signaling pathways. Pathway Activators: Pyrintegrin, PS-48; Pathway Inhbitors: Pluripotin, PD0325901, PD98059, Reversine IWP-2 WNT: The WNT pathway regulates differentiation to the mesoendodermal lineages, induces self-renewal of PSCs, and aids in reprogramming. IWP-3 Pathway Activators: BIO, CHIR99021, Kenpaullone, SB216763; Pathway Inhibitors: IWP-2, IWP-3, IWP-4, -
Monoclonal Antibodies and Small-Molecule Drugs: WHAT GENERAL NEUROLOGISTS NEED to KNOW
THIS CONTENT IS SPONSORED BY AMGEN INC. AND NOVARTIS PHARMACEUTICALS CORPORATION USA-334-83498 Monoclonal Antibodies and Small-Molecule Drugs: WHAT GENERAL NEUROLOGISTS NEED TO KNOW APRIL 2020 I VOL. 28 NO. 4 A Member of the Network Introduction plasma concentration 1–8 days) than IV, but this route permits self- Numerous drug modalities have been approved to treat neurologic administration at home.9,22 diseases, including small-molecule drugs (SMDs) and biologics SMDs generally have wide distribution into tissues, organs and such as monoclonal antibodies (mAbs).1-3 While both are consid- plasma.10,23 They are metabolized by CYP450 enzymes via oxidation, ered targeted therapies,2-7 each has unique characteristics that may leading to renal elimination in the urine, and by conjugation reac- affect their use in clinical practice.5,8,9 This article describes the gen- tions (eg, glucuronidation), leading to hepatic/biliary elimination in eral characteristics of SMDs and mAbs and discusses some of their the stool.10,24,25 mAbs have a small range of distribution.10,23 Particu- safety implications relevant to their use by general neurologists in larly relevant to neurology, therapeutic mAbs do not readily cross clinical practice. the blood–brain barrier and therefore have minimal distribution in the central nervous system (CNS).8,9 Therapeutic mAbs are also Characteristics of SMDs and mAbs too large for clearance by renal or hepatic mechanisms, and instead The general characteristics and pharmacokinetics (PK) of are metabolized by two primary -
Computer-Aided Drug Design: a Practical Guide
Computer-Aided Drug Design: A Practical Guide Forrest Smith, Ph.D. Department of Drug Discovery and Development Harrison School of Pharmacy Auburn, University History of Drug Design • Natural Products-Ebers Papyrus, 1500 B.C. documents over 700 plant based products used to treat a variety of illnesses • The rise of Organic Chemistry, middle or the 20th Century, semi-synthetic and synthetic drugs • Computers emerge in the late 1980s, CADD with minimal impact • Automation in the 1990s, High Through-put Screening and Robotics, Compound Libraries • CADD has continued to advance since its introduction with improving capabilities Computational Chemistry • Ab initio calculations • Semi-empirical calculations • Molecular Mechanics Molecular Mechanics Global Minimum Force Fields • MM2, MM3, MM4 • MMFF • AMBER • CHARM • OPLS Finding the Global Minimum • Systematic Search • Monte Carlo Methods • Simulated Annealing • Quenched Dynamics Minor Groove Binders Computer-Aided Drug Design • Structure Based Design – Docking – Molecular Dynamics – Free Energy Perturbation • Ligand Based Design-QSAR – COMFA – Pharmacophore Modeling – Shape Based Methods Docking-The Receptor • X-Ray Crystal Structures – RCSB Protein Data Bank (https://www.rcsb.org/) – Private Data • Homology Modeling • Nuclear Magnetic Resonance Docking- The Ligand • Proprietary Ligands • Databases qReal Databases • FDA approved drugs- (http://chemoinfo.ipmc.cnrs.fr/MOLDB/index.html) • Purchasable compounds Zinc 15, currently 100 million compounds (http://zinc15.docking.org/) q Virtual Databases- -
Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery
International Journal of Molecular Sciences Review Mechanisms of Action for Small Molecules Revealed by Structural Biology in Drug Discovery Qingxin Li 1,* and CongBao Kang 2,* 1 Guangdong Provincial Engineering Laboratory of Biomass High Value Utilization, Guangdong Provincial Bioengineering Institute (Guangzhou Sugarcane Industry Research Institute), Guangdong Academy of Sciences, Guangzhou 510316, China 2 Experimental Drug Development Centre (EDDC), Agency for Science, Technology and Research (A*STAR), 10 Biopolis Road, Chromos, #05-01, Singapore 138670, Singapore * Correspondence: [email protected] (Q.L.); [email protected] (C.K.); Tel.: +86-020-84168436 (Q.L.); +65-64070602 (C.K.) Received: 12 June 2020; Accepted: 20 July 2020; Published: 24 July 2020 Abstract: Small-molecule drugs are organic compounds affecting molecular pathways by targeting important proteins. These compounds have a low molecular weight, making them penetrate cells easily. Small-molecule drugs can be developed from leads derived from rational drug design or isolated from natural resources. A target-based drug discovery project usually includes target identification, target validation, hit identification, hit to lead and lead optimization. Understanding molecular interactions between small molecules and their targets is critical in drug discovery. Although many biophysical and biochemical methods are able to elucidate molecular interactions of small molecules with their targets, structural biology is the most powerful tool to determine the mechanisms of action for both targets and the developed compounds. Herein, we reviewed the application of structural biology to investigate binding modes of orthosteric and allosteric inhibitors. It is exemplified that structural biology provides a clear view of the binding modes of protease inhibitors and phosphatase inhibitors. -
Reporting Data from High-Throughput Screening of Small-Molecule Libraries
COMMENTARY Reporting data from high-throughput screening of small-molecule libraries James Inglese, Caroline E Shamu & R Kiplin Guy Publications reporting results of small-molecule screens are becoming more common as academic researchers increasingly make use of high-throughput screening (HTS) facilities. However, no standards have been formally established for reporting small-molecule screening data, and often key information important for the evaluation and interpretation of results is omitted in published HTS protocols. Here, we propose concise guidelines for reporting small-molecule HTS data. High-throughput screening (HTS) is becoming providing a basis for evaluation, comparison in the assay. Controls are used to determine a routine method for identifying probes used in and replication of small-molecule screens. We an assay ‘window’ and validate the biological chemical biology. The flexibility of the process have divided small-molecule screen protocol response. It is often desirable to provide an has allowed numerous and disparate areas of information into five categories: the assay, the indication as to the efficacy of the controls. biology to engage with an equally diverse palate library, the HTS process, the post-HTS analy- For example, here is an assay strategy descrip- of chemistry. However, with this diversity, the sis of data and compound structures, and the tion that might be written for a fluorescence many components associated with HTS—the screen results (Fig. 1). Within each category, polarization assay: bioassay, the assay format, the nature of the we describe key pieces of information that are library, reagent and sample delivery meth- important for interpretation and replication This screen was carried out to identify compounds ods, the detection instrumentation, the level of a screen (Table 1). -
Small Molecule Drug Discovery
Small Molecule Drug Discovery Centre for TIA Pipeline Drug Candidate Accelerator Optimisation TetraQ Other NCRIS facilities Universities, Medical research institutes Other therapeutic areas within TIA Small Molecule Discovery and Development Biological Target Compounds Australian Centre for Integrated Australia Translational Preclinical Drug Medicinal Development Chemistry Facility Australia is ideally positioned to be a major player in the global Pharma ecosystem where risk‑adverse companies are looking to in‑license assets that have demonstrated development potential. To enhance the progression of early stage discoveries through to preclinical development, TIA has formed a Small Molecules Group, an integrated capability network of National Research Infrastructure across Australia. These facilities are committed to providing high quality research infrastructure to support leading‑edge research and to boost innovation in Australia. SUPPORTED BY: CONTACT US: T: (07) 3735 4433 E: [email protected] Level 14, 330 Collins Street, Melbourne VIC 3000 www.therapeuticinnovation.com.au Compounds Australia Capability/services offered: • National compound management and logistics facility for small molecule compound libraries and natural product extract and fraction libraries. • Cost effective compound management, supporting drug discovery through high throughput screening • Provides storage and management of the national open access compound collection, GRIDD’s NatureBank collection and numerous proprietary compound collections. -
Identification and Characterization of a Small Molecule Inhibitor of Formin
Chemistry & Biology Article Identification and Characterization of a Small Molecule Inhibitor of Formin-Mediated Actin Assembly Syed A. Rizvi,1,5 Erin M. Neidt,2,5 Jiayue Cui,1 Zach Feiger,3 Colleen T. Skau,2 Margaret L. Gardel,3 Sergey A. Kozmin,1 and David R. Kovar2,4,* 1Department of Chemistry 2Department of Molecular Genetics and Cell Biology 3Department of Physics 4Department of Biochemistry and Molecular Biology The University of Chicago, Chicago, IL 60637, USA 5These authors contributed equally to this work *Correspondence: [email protected] DOI 10.1016/j.chembiol.2009.10.006 SUMMARY nant tumor function and are highly overexpressed in different cancer cell types including colorectal, carcinoma, leukemia, Formins stimulate actin filament assembly for funda- melanoma, and lymphoid (Favaro et al., 2003; Kitzing et al., mental cellular processes including division, adhe- 2007; Sarmiento et al., 2008; Zhu et al., 2008). Determining for- sion, establishing polarity, and motility. A formin min’s numerous roles is particularly complicated because most inhibitor would be useful because most cells express organisms express multiple isoforms (Goode and Eck, 2007). multiple formins whose functions are not known and For example, there are at least 20 formin genes in plants, 18 in because metastatic tumor formation depends on the mammals, 6 each in Drosophila melanogaster and Caenorhabdi- tis elegans, 3 in fission yeast, and 2 in budding yeast (Higgs, deregulation of formin-dependent processes. We 2005). A major challenge is to elucidate all formin-dependent identified a general small molecule inhibitor of formin cellular functions in both healthy and diseased tissues. homology 2 domains (SMIFH2) by screening com- Formins are multidomain proteins that contain a highly pounds for the ability to prevent formin-mediated conserved actin assembly formin homology 2 FH2 domain and actin assembly in vitro. -
Structure Based Pharmacophore Modeling, Virtual Screening
www.nature.com/scientificreports OPEN Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identifcation of natural anti‑cancer agents targeting XIAP protein Firoz A. Dain Md Opo1,2, Mohammed M. Rahman3*, Foysal Ahammad4, Istiak Ahmed5, Mohiuddin Ahmed Bhuiyan2 & Abdullah M. Asiri3 X‑linked inhibitor of apoptosis protein (XIAP) is a member of inhibitor of apoptosis protein (IAP) family responsible for neutralizing the caspases‑3, caspases‑7, and caspases‑9. Overexpression of the protein decreased the apoptosis process in the cell and resulting development of cancer. Diferent types of XIAP antagonists are generally used to repair the defective apoptosis process that can eliminate carcinoma from living bodies. The chemically synthesis compounds discovered till now as XIAP inhibitors exhibiting side efects, which is making difculties during the treatment of chemotherapy. So, the study has design to identifying new natural compounds that are able to induce apoptosis by freeing up caspases and will be low toxic. To identify natural compound, a structure‑ based pharmacophore model to the protein active site cavity was generated following by virtual screening, molecular docking and molecular dynamics (MD) simulation. Initially, seven hit compounds were retrieved and based on molecular docking approach four compounds has chosen for further evaluation. To confrm stability of the selected drug candidate to the target protein the MD simulation approach were employed, which confrmed stability of the three compounds. Based on the fnding, three newly obtained compounds namely Caucasicoside A (ZINC77257307), Polygalaxanthone III (ZINC247950187), and MCULE‑9896837409 (ZINC107434573) may serve as lead compounds to fght against the treatment of XIAP related cancer, although further evaluation through wet lab is necessary to measure the efcacy of the compounds. -
BUDE: GPU-Accelerated Molecular Docking for Drug Discovery
BUDE A General Purpose Molecular Docking Program Using OpenCL Richard B Sessions 1 The molecular docking problem Proteins typically O(1000) atoms ligand Ligands typically O(100) atoms predicted complex receptor 1 Sampling (6-degrees of freedom) EMC 2 Binding affinity prediction EFE-FF 2 An atom-atom based forcefield parameterised according to atom type, analagous to standard molecular mechanics 3 Empirical Free Energy Forcefield McIntosh-Smith, S., et al., Benchmarking Energy Efficiency, Power Costs and Carbon Emissions on Heterogeneous Systems. soft core Computer Journal, 2012. 55(2): p. 192-205. Re-docking a ligand into the Xray Structure (good prediction == low RMSD) 1CIL (Human carbonic anhydrase II) RMSD ~ 0.2 Å 5 Another example 1EZQ (Human Factor XA) RMSD ~ 1.2 Å 6 Accuracy of Pose Prediction (re-docking the BindingDB validation set, 84 complexes) www.bindingdb.org 7 Binding Energy Prediction: is BUDE any better? Mike Hann’s 2006 test of docking software Yes – better but not perfect! 8 BUDE Simplified Flow Diagram (C++/OpenCL) Start BUDE Enter Initial End BUDE Data Yes Data Error(s)? Reading Print Help Yes No Error(s)? Write Control File Prepare Data for Docking No Docking Info Type Docking End BUDE Act on No Option Small Yes Large Error(s)? Site Docking Surface Docking Generate Surface Pairs Calculate Energies Do Docking Print Results No Do Generation Rank Energies Host Job Parallel EMC Code? Score Results Accelerated Job Yes Yes Last No Generation 9 BUDE’s heterogeneous approach 1. Discover all OpenCL platforms/devices, inc. both CPUs and GPUs 2. Run a micro benchmark on each device, ideally a short piece of real work 3. -
Cell Communication and Signaling Mechanisms Terms to Learn
LQB383 Testbank Week 8 – Cell Communication and Signaling Mechanisms Terms to learn – match the terms to the definitions -------------------------------------------------------------------------------------------------------------------------- Adaptor Intracellular signaling protein Morphogen Endocrine cell Gap junction Neurotransmitter Hormone Receptor Extracellular signal molecule Signaling cascade Steroid hormone Synaptic signaling Paracrine signaling Second messenger Autocrine signaling Nuclear receptor family Interaction domain Contact-dependent signaling Definitions 1. General term for a protein that binds a specific extracellular molecule (ligand) and initiates a response in a cell. 2. Communicating cell-cell junction that allows ions and small molecules to pass from the cytoplasm of one cell to the cytoplasm of another. 3. Hydrophobic signaling molecule with characteristic four-ringed structure derived from cholesterol. 4. Short-range cell-cell communication via secreted local mediators that act on adjacent cells. 5. Specialised cell that secretes a hormone into the blood 6. The cell responds to its own secreted molecules. 7. Small signaling molecule secreted by the presynaptic nerve cell at a chemical synapse to relay the signal to the postsynaptic cell. 8. Small molecule that is formed in the cytosol, or released into it, in response to an extracellular signal, and that helps to relay the signal in the interior of the cell. 9. Molecule from the outside of the cell that communicates the behaviour or actions of other cells in the environment and elicits an appropriate response. 10. General term for a signal relay chain containing multiple amplification steps. 1 Receptor 2 Gap junction 3 Steroid hormone 4 Paracrine signaling 5 Endocrine cell 6 Autocrine signaling 7 Neurotransmitter 8 Second messenger 9 Extracellular signal molecule 10 Signaling cascade Multiple Choice Questions 1. -
Using Small Molecules to Control Stem Cell Growth and Differentiation
Using Small Molecules to Control Stem Cell Growth and Differentiation Kirsty E. Clarke1, Victoria B. Christie1, Andy Whiting2 Introduction and Stefan A. Przyborski1 1Biological Sciences, Durham University, Small molecules are routinely used to manipulate signaling South Road, Durham, DH1 3LE, UK pathways during the in vitro culture of cells. Signaling pathways that control cell proliferation and differentiation are important 2 Department of Chemistry, Durham University, targets for small molecules in the culture of stem cells. Targeting South Road, Durham, DH1 3LE, UK pathways such as the canonical Wnt, transforming growth Correspondence e-mail: [email protected] factor-β (TGF-β) and retinoic acid signaling pathways can be Kirsty Clarke and Victoria Christie are research scientists useful to enhance and maintain the proliferation of stem cells, within the laboratory of Professor Stefan Przyborski at Durham or to guide stem cell fate toward specific lineages in con trolled University. Research in Professor Przyborski’s group focuses on differentiation. This review provides a brief overview of the the development and application of technology to improve the small molecules that interact with the primary signaling path- growth, differentiation and function of cultured cells, including ways that govern stem cell proliferation and differentiation the use of small molecules that control stem cell fate. to mediate stem cell behavior, along with the role of small Professor Whiting is an organic chemist and a long-standing molecules in the dedifferentiation of somatic cells to create collaborator of Professor Przyborski, working on the design and populations of pluripotent stem cells. development of small molecules to control cellular behavior.